Current Report Filing (8-k)
December 10 2019 - 2:31PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of The
Securities Exchange Act of 1934
Date of Report (Date of Earliest Event Reported):
December 10, 2019
Titan
Pharmaceuticals, Inc.
(Exact name of registrant as specified in
its charter)
Delaware
(State or other jurisdiction of incorporation)
001-13341
|
94-3171940
|
(Commission File Number)
|
(IRS Employer Identification No.)
|
400 Oyster Point Blvd., Suite 505, South
San Francisco, CA 94080
(Address of principal executive offices
and zip code)
650-244-4990
(Registrant's telephone number including
area code)
(Registrant's former name or former address,
if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of registrant under any of the following provisions:
|
¨
|
Written communications pursuant to Rule 425 under the
Securities Act (17 CFR 230.425)
|
|
¨
|
Soliciting material pursuant to Rule 14a-12(b) under
the Exchange Act (17 CFR 240.14a-12(b))
|
|
¨
|
Pre-commencement communications pursuant to Rule 14d-2(b)
under the Exchange Act (17 CFR 240.14d-2(b))
|
|
¨
|
Pre-commencement communications pursuant to Rule 13e-4(c)
under the Exchange Act (17 CFR 240.13e-4(c))
|
Indicate by check mark whether the registrant is an emerging
growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities
Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ¨
If an emerging growth company, indicate by check mark if the
registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards
provided pursuant to Section 13(a) of the Exchange Act. ¨
Securities registered pursuant
to Section 12(b) of the Act:
Title of each class
|
|
Trading Symbol(s)
|
|
Name of each exchange on which registered
|
Common Stock, par value $0.001
|
|
TTNP
|
|
Nasdaq Capital Market
|
|
Item 7.01.
|
Regulation FD Disclosure.
|
Titan Pharmaceuticals, Inc. has updated its corporate presentation,
which will be posted on its website and used for future presentations. A copy of the presentation is attached hereto as Exhibit
99.1 and incorporated herein by reference.
The foregoing information, including the presentation attached
hereto as an exhibit, is being furnished pursuant to Item 7.01 of this Current Report and shall not be deemed “filed”
for the purposes of Section 18 of the Securities and Exchange Act of 1934, as amended, or otherwise subject to the liabilities
of that Section. This information shall not be incorporated by reference into any registration statement pursuant to the Securities
Act of 1933, as amended
|
Item 9.01.
|
Financial Statements and Exhibits.
|
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act
of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
|
TITAN PHARMACEUTICALS, INC.
|
|
|
|
By:
|
/s/ Sunil Bhonsle
|
|
|
Name: Sunil Bhonsle
Title: Chief Executive Officer and President
|
Dated:
December 10, 2019
Titan Pharmaceuticals (NASDAQ:TTNP)
Historical Stock Chart
From Aug 2024 to Sep 2024
Titan Pharmaceuticals (NASDAQ:TTNP)
Historical Stock Chart
From Sep 2023 to Sep 2024